1. Page
2.2. Followed by Consolidation Therapy with Pemetrexed in Locally 
4. LY231514
5.2.2.2. LY231514
6.3. LY231514
9. LY231514
1. Introduction
1.2. Non Small Cell Lung Cancer
1.3.1. Current Standard of Care
1.4. Pemetrexed
1.4.1. Pemetrexed Development in Lung Cancer
2. Objectives
2.1. Primary Objective
2.2. Secondary Objectives
3. Investigational Plan
3.1. Summary of Study Design
3.1.1. Study Extensions
3.2. Discussion of Design and Control
4. Study Population
4.1. Patients enrolled in this study should not be considered candidates for any therapy beyond 
4.2. Exclusion Criteria
4.2.1. Rationale for Exclusion of Certain Study Candidates
4.3. Discontinuations
4.3.1. Discontinuation of Patients
4.3.2. Discontinuation of Study Sites
4.3.3. Discontinuation of the Study
5. Treatment
5.1. Treatments Administered
5.1.1. Concurrent Phase
5.1.2. Recovery Phase
5.1.3. Consolidation Phase
5.1.4. Postdiscontinuation Follow Up
5.2. Materials and Supplies
5.2.1. Concurrent Phase
5.2.1.1.1. Pemetrexed
5.2.1.1.2. Folic Acid
5.2.1.1.3. Vitamin B12
5.2.1.1.4. Dexamethasone
5.2.1.1.5. Cisplatin
5.2.1.1.6. Thoracic Radiation Therapy
5.2.1.1.6.1. Dose Specifications
5.2.1.1.6.2. Variations of Dose Prescription
5.2.1.1.6.4. Treatment Planning/Target Volumes
5.2.1.1.6.5. Treatment Planning
5.2.1.1.6.6. Documentation
5.2.1.1.6.7. Organs at Risk
5.2.1.1.6.8. Treatment Quality Assurance and Compliance with Protocol Defined 
5.2.1.1.6.9. Radiation Adverse Events and Interruption
5.2.1.2. Etoposide/Cisplatin/Radiation Therapy
5.2.1.2.1. Etoposide
5.2.1.2.2. Cisplatin
5.2.1.2.3. Radiation Therapy
5.2.2. Consolidation Phase
5.2.2.1. Pemetrexed
5.2.2.2. Platinum Based Doublets
5.2.2.2.1. Etoposide/Cisplatin
5.2.2.2.2. Vinorelbine/Cisplatin
5.2.2.2.3. Paclitaxel/Carboplatin
5.3. Method of Assignment to Treatment
5.4. Rationale for Selection of Doses in the Study
5.4.1. Dose Delays/Dose Modifications
5.4.1.1. Concurrent Phase
5.4.1.1.1. Pemetrexed/Cisplatin
5.4.1.1.2. Etoposide/Cisplatin
5.4.1.1.3. Radiation Treatment Interruptions
5.4.1.2. Consolidation Phase
5.4.1.2.1. Pemetrexed
5.4.1.2.1.1. Hematologic Toxicities
5.4.1.2.1.2. Nonhematologic Toxicities
5.4.1.2.2. Etoposide/Cisplatin
5.4.1.2.3. Vinorelbine/Cisplatin
5.4.1.2.4. Paclitaxel/Carboplatin
5.4.1.2.5. Carboplatin Toxicity and Dose Reduction
5.5. Selection and Timing of Doses
5.5.1. Special Treatment Considerations
5.5.1.1. Clinically Significant Effusions
5.5.1.2. Creatinine Clearance
5.5.1.3. Treatment Delays for Arm A Due to Insufficient Folic Acid or Vitamin B12
5.6. Blinding
5.7. Concomitant Therapy
5.7.1. Colony Stimulating Factors
5.7.2. Nonsteroidal Anti Inflammatory Drugs
5.7.3. Leucovorin
5.7.4. Therapy for Diarrhea
5.7.5. Therapy for Febrile Neutropenia
5.7.6. Antiemetic Therapy
5.7.7. Drug Drug Interactions
5.7.8. Pleural Effusion
5.8. Treatment Compliance
6.1. Efficacy Measures
6.1.1. Primary Efficacy Measure
6.1.2. Secondary Efficacy Measures
6.2. Patient Reported Outcome Measures
6.2.1. Swallowing Diary
6.3. Safety Evaluations
6.3.1. Adverse Events
6.3.1.1. Serious Adverse Events
6.3.2. Laboratory Tests
6.3.3. Safety Monitoring
6.3.4. Complaint Handling
6.4. Sample Collection and Testing
6.4.1. Samples for Standard Laboratory Testing
6.4.2. Samples for Central Pathology Review
6.5. Appropriateness of Measurements
7. Data Quality Assurance
7.1. Direct Data Entry and Computerized Systems
8. Sample Size and Statistical Methods
8.1. Determination of Sample Size
8.2. Statistical and Analytical Plans
8.2.1. General Considerations
8.2.1.1. Qualifications for Efficacy Analysis
8.2.1.2. Qualifications for Patient Reported Outcomes (PROs)
8.2.1.3. Qualifications for Safety Analysis
8.2.2. Patient Disposition
8.2.3. Patient Characteristics
8.2.4. Concomitant Therapy
8.2.5. Treatment Compliance
8.2.6. Primary Outcome and Methodology
8.2.7. Secondary Efficacy Analyses
8.2.8. Patient Reported Outcomes Analyses
8.2.9. Safety Analyses
8.2.10. Subgroup Analyses
8.2.11. Interim Analyses
9.1. The investigator is responsible for ensuring that the patient understands the risks and benefits of 
9.2. Ethical Review
9.3. Regulatory Considerations
9.3.2. Protocol Signatures
9.3.3. Final Report Signature
10. References
2006. Long term survival with concurrent chemoradiation therapy followed by consolidation 
12 d 
24 d 
12 d 
24 d 
12 d 
24 d 
12 d 
24 d 
5.1.3. Consolidation Phase
5.2.5.2.1. Concurrent Phase
5.2.1.1. Pemetrexed/Cisplatin/Thoracic Radiation Therapy
